Compare GROY & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROY | FLGT |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 938.2M | 867.4M |
| IPO Year | 2021 | 2016 |
| Metric | GROY | FLGT |
|---|---|---|
| Price | $4.20 | $26.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $5.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 3.4M | 206.0K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,464,000.00 | ★ $315,549,000.00 |
| Revenue This Year | $72.11 | $16.84 |
| Revenue Next Year | $100.63 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.30 | 13.61 |
| 52 Week Low | $1.16 | $14.57 |
| 52 Week High | $4.49 | $31.04 |
| Indicator | GROY | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 42.88 |
| Support Level | $4.08 | $26.63 |
| Resistance Level | $4.23 | $28.26 |
| Average True Range (ATR) | 0.18 | 0.62 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 88.44 | 4.59 |
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.